Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic factors in systemic lupus erythematosus.

A J Swaak1, J C Nossent, R J Smeenk

  • 1Department of Rheumatology, Dr Daniel den Hoed Clinic, Rotterdam, The Netherlands.

Rheumatology International
|January 1, 1991
PubMed
Summary

Prognosis for Systemic Lupus Erythematosus (SLE) patients has improved, but advances in recognition and treatment may not be the primary drivers. Specific disease manifestations like lupus nephritis and disease activity significantly impact survival rates more than demographics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Intra-prostatic recurrences after radiotherapy with focal boost: Location and dose mapping in the FLAME trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

Longitudinal Image Data for Outcome Modeling.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure.

ESMO open·2023
Same author

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial.

BMC cancer·2022
Same author

Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.

BMC cancer·2022

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic Lupus Erythematosus (SLE) prognosis has significantly improved over the last four decades.
  • Commonly cited reasons include enhanced disease recognition and treatment advancements.

Purpose of the Study:

  • To critically evaluate the factors contributing to improved SLE patient survival.
  • To identify the most impactful factors influencing SLE outcomes.

Main Methods:

  • Literature review and analysis of factors affecting SLE patient survival.
  • Correlation analysis of disease duration, survival rates, and publication frequency.
  • Assessment of the impact of specific disease manifestations, disease course, and demographic factors on survival.

Related Experiment Videos

Main Results:

  • Survival rates and disease duration have increased linearly with the volume of SLE publications since 1950.
  • Specific disease manifestations, particularly lupus nephritis, and the overall disease course (number of exacerbations) are major determinants of survival.
  • Factors such as sex and race have a lesser impact on survival compared to disease-specific factors.
  • Socio-economic status and age at onset do not significantly affect patient outcomes.

Conclusions:

  • The improvement in SLE prognosis is influenced more by disease-specific factors than by general advancements in medical care or demographics.
  • Lupus nephritis and disease activity are critical indicators for predicting SLE patient survival.
  • Further research should focus on understanding and managing these specific disease aspects to optimize patient outcomes.